@article{TianLinQuetal.2024,
  author    = {Tian, Yu and Lin, Yi and Qu, Conghui and Arndt, Volker and Baurley, James W. and Berndt, Sonja I. and Bien, Stephanie A. and Bishop, D. Timothy and Brenner, Hermann and Buchanan, Daniel D. and Budiarto, Arif and Campbell, Peter T. and Carreras-Torres, Robert and Casey, Graham and Chan, Andrew T. and Chen, Rui and Chen, Xuechen and Conti, David V. and D{\´i}ez-Obrero, Virginia and Dimou, Niki and Drew, David A. and Figueiredo, Jane C. and Gallinger, Steven and Giles, Graham G. and Gruber, Stephen B. and Gunter, Marc J. and Harlid, Sophia and Harrison, Tabitha A. and Hidaka, Akihisa and Hoffmeister, Michael and Huyghe, Jeroen R. and Jenkins, Mark A. and Jordahl, Kristina M. and Joshi, Amit D. and Keku, Temitope O. and Kawaguchi, Eric and Kim, Andre E. and Kundaje, Anshul and Larsson, Susanna C. and Marchand, Loic Le and Lewinger, Juan Pablo and Li, Li and Moreno, Victor and Morrison, John and Murphy, Neil and Nan, Hongmei and Nassir, Rami and Newcomb, Polly A. and Ob{\´o}n-Santacana, Mireia and Ogino, Shuji and Ose, Jennifer and Pardamean, Bens and Pellatt, Andrew J. and Peoples, Anita R. and Platz, Elizabeth A. and Potter, John D. and Prentice, Ross L. and Rennert, Gad and Ruiz-Narvaez, Edward A. and Sakoda, Lori C. and Schoen, Robert E. and Shcherbina, Anna and Stern, Mariana C. and Su, Yu-Ru and Thibodeau, Stephen N. and Thomas, Duncan C. and Tsilidis, Konstantinos K. and Duijnhoven, Fr{\"a}nzel J. B. van and Guelpen, Bethany van and Visvanathan, Kala and White, Emily and Wolk, Alicja and Woods, Michael O. and Wu, Anna H. and Peters, Ulrike and Gauderman, W. James and Hsu, Li and Chang-Claude, Jenny},
  title     = {Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk},
  journal   = {British Journal of Cancer},
  issn      = {0007-0920},
  doi       = {10.25968/opus-3098},
  institution = {Fakult{\"a}t III - Medien, Information und Design},
  pages     = {10},
  year      = {2024},
  abstract  = {Background: Menopausal hormone therapy (MHT), a common treatment to relieve symptoms of menopause, is associated with a lower risk of colorectal cancer (CRC). To inform CRC risk prediction and MHT risk-benefit assessment, we aimed to evaluate the joint association of a polygenic risk score (PRS) for CRC and MHT on CRC risk. Methods: We used data from 28,486 postmenopausal women (11,519 cases and 16,967 controls) of European descent. A PRS based on 141 CRC-associated genetic variants was modeled as a categorical variable in quartiles. Multiplicative interaction between PRS and MHT use was evaluated using logistic regression. Additive interaction was measured using the relative excess risk due to interaction (RERI). 30-year cumulative risks of CRC for 50-year-old women according to MHT use and PRS were calculated. Results: The reduction in odds ratios by MHT use was larger in women within the highest quartile of PRS compared to that in women within the lowest quartile of PRS (p-value = 2.7 × 10-8). At the highest quartile of PRS, the 30-year CRC risk was statistically significantly lower for women taking any MHT than for women not taking any MHT, 3.7\% (3.3\%-4.0\%) vs 6.1\% (5.7\%-6.5\%) (difference 2.4\%, P-value = 1.83 × 10-14); these differences were also statistically significant but smaller in magnitude in the lowest PRS quartile, 1.6\% (1.4\%-1.8\%) vs 2.2\% (1.9\%-2.4\%) (difference 0.6\%, P-value = 1.01 × 10-3), indicating 4 times greater reduction in absolute risk associated with any MHT use in the highest compared to the lowest quartile of genetic CRC risk. Conclusions: MHT use has a greater impact on the reduction of CRC risk for women at higher genetic risk. These findings have implications for the development of risk prediction models for CRC and potentially for the consideration of genetic information in the risk-benefit assessment of MHT use.},
  subject      = {Dickdarmkrebs},
  language  = {en}
}